The effect of voglibose on metabolic profiles in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of clinical trials.

Aged Biomarkers / blood Cholesterol, LDL / blood Diabetes Mellitus, Type 2 / blood Energy Metabolism / drug effects Female Glycated Hemoglobin / metabolism Glycoside Hydrolase Inhibitors / adverse effects Humans Inositol / adverse effects Male Middle Aged Randomized Controlled Trials as Topic Treatment Outcome
Diabetes mellitus Meta-analysis Metabolic profiles Voglibose

Journal

Pharmacological research
ISSN: 1096-1186
Titre abrégé: Pharmacol Res
Pays: Netherlands
ID NLM: 8907422

Informations de publication

Date de publication:
09 2020
Historique:
received: 01 03 2020
revised: 12 05 2020
accepted: 29 05 2020
pubmed: 7 6 2020
medline: 6 7 2021
entrez: 7 6 2020
Statut: ppublish

Résumé

The effect of voglibose on metabolic homeostasis is not well characterized. Therefore, we conducted a systematic review and meta-analysis of clinical trials assessing the effect of voglibose on metabolic profile in patients with type 2 diabetes mellitus (T2DM). Systematic searches were conducted in PubMed, Scopus, Embase, Google Scholar, Web of Science and Cochrane Library to identify clinical trials assessing the effects of voglibose supplementation on cardio-metabolic profile from incept up to 29 July 2019. Data was pooled using fixed- or random-effect models and weighted mean difference (WMD) as the effect size. Eight clinical trials from 1094 reports, were eligible for inclusion. Pooled findings identified significant reductions in hemoglobin A1c (HbA1c) (WMD= -0.27; 95 %CI -0.49 to -0.05; P = 0.01; I The current meta-analysis identified a decrease in HbA1c and an increase in LDL-cholesterol with administration of voglibose. However, no significant effect was observed on FBS, insulin, bodyweight, BMI, adiponectin, triglycerides, total- and HDL-cholesterol levels.

Identifiants

DOI: 10.1016/j.phrs.2020.104988 PMID: 32504833
pubmed: 32504833
pii: S1043-6618(20)31296-2
doi: 10.1016/j.phrs.2020.104988
pii:
doi:

Substances chimiques

Biomarkers 0
Cholesterol, LDL 0
Glycated Hemoglobin A 0
Glycoside Hydrolase Inhibitors 0
hemoglobin A1c protein, human 0
Inositol 4L6452S749
voglibose S77P977AG8

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

104988

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Peyman Nowrouzi-Sohrabi (P)

Department of Biochemistry, Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.

Reza Tabrizi (R)

Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran.

Shahla Rezaei (S)

School of Nutrition and Food Sciences, Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.

Fatemeh Jafari (F)

Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran.

Kamran Hessami (K)

Maternal-Fetal Medicine Research Center, Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.

Mehdi Abedi (M)

Department of Pharmaceutical Nanotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.

Mohammad Jalali (M)

Nutrition Research Center, Student Research Committee, Shiraz University of Medical Sciences, Iran.

Pedram Keshavarzi (P)

Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran.

Saeed Shahabi (S)

Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran.

Ali Asghar Kolahi (AA)

Social Determinants of Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Kristin Carson-Chahhoud (K)

Australian Centre for Precision Health, School of Health Sciences, University of South Australia, Australia.

Amirhossein Sahebkar (A)

Halal Research Center of IRI, FDA, Tehran, Iran; Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: sahebkara@mums.ac.ir.

Saeid Safiri (S)

Social Determinants of Health Research Center, Department of Community Medicine, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; Sports Medicine Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran; Physical Medicine and Rehabilitation Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: saeidsafiri@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › The effect of voglibose on metabolic profiles...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › The effect of voglibose on metabolic profiles...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Lipoprotéines › Lipoprotéines LDL › Cholestérol LDL › The effect of voglibose on metabolic profiles...
questionsmedicales.fr › Maladies endocriniennes › Diabète › Diabète de type 2 › The effect of voglibose on metabolic profiles...
questionsmedicales.fr › Métabolisme › Métabolisme énergétique › The effect of voglibose on metabolic profiles...
questionsmedicales.fr › Facteurs biologiques › Toxines biologiques › Produits terminaux de glycation avancée › Protéines glyquées › Protéine glycosylée sérique › Hémoglobine glycosylée › The effect of voglibose on metabolic profiles...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hypoglycémiants › Inhibiteurs des glycoside hydrolases › The effect of voglibose on metabolic profiles...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The effect of voglibose on metabolic profiles...
questionsmedicales.fr › Glucides › Polyols › Inositol › The effect of voglibose on metabolic profiles...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › The effect of voglibose on metabolic profiles...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études cliniques comme sujet › Essais cliniques comme sujet › Essais cliniques contrôlés comme sujet › Essais contrôlés randomisés comme sujet › The effect of voglibose on metabolic profiles...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › The effect of voglibose on metabolic profiles...